Update: On September 1, 2020, BRDD revised its Report to correct the “Biosimilars: Market Authorizations” tables.
The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD; formerly BGTD) and the Natural and Non-Prescription Health Products Directorate (NNHPD) have released their Drug Submission Performance Annual Reports for Fiscal Year 2019-2020. The reports contain information regarding pharmaceutical, biologic and radiopharmaceutical, and non-prescription and disinfectant drug submission review activity over five consecutive fiscal years (April 1 to March 31) from 2015-2016 to 2019-2020.
Related Publications & Articles
-
U.S. FDA authorizes Florida plan to import drugs in bulk from Canada
A proposed program by the state of Florida to import certain prescription drugs from Canada has received the approval of the United States Food and Drug Administration (FDA): FDA news release on Janua...Read More -
Permanent regulatory framework now broadened beyond COVID-19 medical devices
On January 3, 2024, Regulations Amending the Medical Devices Regulations (Medical Devices for an Urgent Public Health Need) came into force.Read More -
Health Canada provides clarifications on application of the definition of Canadian reference product based on Dormant status
On January 26, 2024, Health Canada published a notice confirming the Department will apply the definition of CRP consistent with its proposal.Read More